CIK 0001512762
- Accelerated filer
- Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273615821
- Phone
- +1 650-649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- 4 Other disposition Director disposed of 983,221 shares (other)
- 4 Open-market sale Chief Operating Officer sold 5,000 shares at $19.37 ($96,851)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Operating Officer sold 15,000 shares at $18.25 ($273,687)
- 4 Exercise or conversion President & CEO acquired 29,994 shares (option exercise)
- 4 Open-market sale Director sold 54,997 shares at $17.58 ($966,759)
- 4 Open-market sale Chief Operating Officer sold 2,500 shares at $17.22 ($43,050)
- 4 Open-market sale Director sold 200,000 shares at $17.15 ($3,430,020)
- 4 Open-market sale Chief Financial Officer sold 1,278 shares at $17.66 ($22,569)
- 4 Open-market sale Chief Operating Officer sold 3,093 shares at $17.17 ($53,107)
- 4 Open-market sale Chief Operating Officer sold 10,150 shares at an average $16.30 ($165,400)
- 4 Open-market sale Director sold 118,066 shares at an average $20.12 ($2,375,409)
- 4 Open-market sale Chief Financial Officer sold 3,159 shares at $22.33 ($70,552)
- 4 Open-market sale Chief Operating Officer sold 10,000 shares at an average $21.64 ($216,390)
- 4 Open-market sale Chief Operating Officer sold 10,000 shares at an average $19.59 ($195,931)
- 4 Open-market sale Chief Financial Officer sold 6,318 shares at an average $19.85 ($125,424)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 9 of 20 · 399 filings